“The gatekeepers in prevention”: Community pharmacist perceptions of their role in the opioid epidemic

References

• Haffajee RL, Frank RG. Making the opioid public health emergency effective. JAMA Psychiatry. 2018;75(8):767–768.
   PubMed Web of Science ®Google Scholar
• Shafer E, Bergeron N, Smith-Ray R, Robson C, O'Koren R. A nationwide pharmacy chain responds to the opioid epidemic. J Am Pharm Assoc. 2017;57(2S):S123–S129.
   Google Scholar
• Lim JK, Bratberg JP, Davis CS, Green TC, Walley AY. Prescribe to prevent: overdose prevention and naloxone rescue kits for prescribers and pharmacists. J Addict Med. 2016;10(5):300–308.
   PubMed Web of Science ®Google Scholar
• Cochran G, Hruschak V, DeFosse B, Hohmeier KC. Prescription opioid abuse: pharmacists' perspective and response. Integr Pharm Res Pract. 2016;5:65–73.
   PubMed Web of Science ®Google Scholar
• Jones MR, Viswanath O, Peck J, Kaye AD, Gill JS, Simopoulos TT. A brief history of the opioid epidemic and strategies for pain medicine. Pain Ther. 2018;7(1):13–21.
   PubMed Web of Science ®Google Scholar
• Dowell D, Zhang K, Noonan RK, Hockenberry JM. Mandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates. Health Aff (Millwood)). 2016;35(10):1876–1883.
   PubMed Web of Science ®Google Scholar
• Meyerson BE, Agley JD, Davis A, et al. Predicting pharmacy naloxone stocking and dispensing following a statewide standing order, Indiana 2016. Drug Alcohol Depend. 2018;188:187–192.
   PubMed Web of Science ®Google Scholar
• Reifler LM, Droz D, Bailey JE, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012;13(3):434–442.
   PubMed Web of Science ®Google Scholar
• Fink DS, Schleimer JP, Sarvet A, et al. Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: a systematic review. Ann Intern Med. 2018;168(11):783–790.
   PubMed Web of Science ®Google Scholar
• Rutkow L, Chang HY, Daubresse M, Webster DW, Stuart EA, Alexander GC. Effect of Florida's prescription drug monitoring program and Pill Mill Laws on opioid prescribing and use. JAMA Intern Med. 2015;175(10):1642–1649.
   PubMed Web of Science ®Google Scholar
• Moyo P, Simoni-Wastila L, Griffin BA, et al. Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 US States. Addiction. 2017;112(10):1784–1796.
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain – United States, 2016. MMWR Recomm Rep. 2016;65(1):1–49.
   PubMed Web of Science ®Google Scholar
• Evoy KE, Hill LG, Groff L, Mazin L, Carlson CC, Reveles KR. Naloxone accessibility without a prescriber encounter under standing orders at community pharmacy chains in Texas. JAMA. 2018;320(18):1934–1937.
   PubMed Web of Science ®Google Scholar
• Chen Q, Larochelle MR, Weaver DT, et al. Prevention of prescription opioid misuse and projected overdose deaths in the United States. JAMA Netw Open. 2019;2(2):e187621.
   PubMed Web of Science ®Google Scholar
• College of Psychiatric and Neurologic Pharmacists. Opioid use disorders: intervention for community pharmacist; 2016. https://cpnp.org/ed/presentation/2016/opioid-use-disorders-interventions-community-pharmacists?view=link-0-1471880668. Accessed March 25, 2020.
   Google Scholar
• American Associations of Colleges of Pharmacy. Curricular guidelines for pharmacy: substance abuse and addictive disease; 2010. https://www.aacp.org/sites/default/files/Curricular%20Guidelines%20for%20Pharmacy%20-%20Substance%20Abuse%20and%20Addictive%20Disease.pdf. Accessed March 25, 2020.
   Google Scholar
• Thomas K, Muzyk AJ. Surveys of substance use disorders education in US pharmacy programs. Ment Health Clin. 2018;8(1):14–17.
   PubMedGoogle Scholar
• Cox N, Tak CR, Cochella SE, Leishman E, Gunning K. Impact of pharmacist previsit input to providers on chronic opioid prescribing safety. J Am Board Fam Med. 2018;31(1):105–112.
   PubMed Web of Science ®Google Scholar
• Strand MA, Eukel H, Burck S. Moving opioid misuse prevention upstream: a pilot study of community pharmacists screening for opioid misuse risk. Res Social Adm Pharm. 2019;15(8):1032–1036.
   PubMed Web of Science ®Google Scholar
• Jacobs SC, Son EK, Tat C, Chiao P, Dulay M, Ludwig A. Implementing an opioid risk assessment telephone clinic: outcomes from a pharmacist-led initiative in a large Veterans Health Administration primary care clinic, December 15, 2014–March 31, 2015. Subst Abus. 2016;37(1):15–19.
   PubMed Web of Science ®Google Scholar
• DiPaula BA, Menachery E. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients. J Am Pharm Assoc. 2015;55(2):187–192.
   Google Scholar
• Bounthavong M, Harvey MA, Wells DL, et al. Trends in naloxone prescriptions prescribed after implementation of a national academic detailing service in the Veterans Health Administration: a preliminary analysis. J Am Pharm Assoc. 2017;57(2S):S68–S72.
   Google Scholar
• Giannitrapani KF, Glassman PA, Vang D, et al. Expanding the role of clinical pharmacists on interdisciplinary primary care teams for chronic pain and opioid management. BMC Fam Pract. 2018;19(1):107.
   PubMedGoogle Scholar
• Bratberg JP, Smothers ZPW, Collins L, Erstad B, Ruiz Veve J, Muzyk A. Pharmacists and the opioid crisis: a narrative review of pharmacists' practice roles. J Am Coll Clin Pharm. 2019;3:478–484.
   Google Scholar
• Kelling SE, Rondon-Begazo A, DiPietro Mager NA, Murphy BL, Bright DR. Provision of clinical preventive services by community pharmacists. Prev Chronic Dis. 2016;13:E149.
   PubMed Web of Science ®Google Scholar
• Hagemeier NE, Gray JA, Pack RP. Prescription drug abuse: a comparison of prescriber and pharmacist perspectives. Subst Use Misuse. 2013;48(9):761–768.
   PubMed Web of Science ®Google Scholar
• Murphy AL, Phelan H, Haslam S, Martin-Misener R, Kutcher SP, Gardner DM. Community pharmacists' experiences in mental illness and addictions care: a qualitative study. Subst Abuse Treat Prev Policy. 2016;11:6.
   PubMed Web of Science ®Google Scholar
• Hartung DM, Hall J, Haverly SN, et al. Pharmacists' role in opioid safety: a focus group investigation. Pain Med. 2018;19(9):1799–1806.
   PubMed Web of Science ®Google Scholar
• Meyerson BA, Jayawardene W, Eldridge LA, et al. Feasibility and acceptability of a proposed pharmacy-based harm reduction intervention to reduce opioid overdose, HIV and hepatitis C. Res Social Adm Pharm. 2019;16:699–709.
   PubMed Web of Science ®Google Scholar
• Balough MM, Nwankpa S, Unni EJ. Readiness of pharmacists based in Utah about pain management and opioid dispensing. Pharmacy. 2019;7(1):11.
   Web of Science ®Google Scholar
• Agley J, Meyerson B, Eldridge L, et al. Just the fax, please: updating electronic/hybrid methods for surveying pharmacists. Res Social Adm Pharm. 2019;15(2):226–227.
   PubMed Web of Science ®Google Scholar
• Meyerson BE, Davis A, Agley JD, et al. Predicting pharmacy syringe sales to people who inject drugs: Policy, practice and perceptions. Int J Drug Policy. 2018;56:46–53.
   PubMed Web of Science ®Google Scholar
• Agley J, Carlson JM, McNelis AM, et al. ‘Asking' but Not ‘Screening': assessing physicians' and nurses' substance-related clinical behaviors . Subst Use Misuse. 2018;53(11):1834–1839.
   PubMed Web of Science ®Google Scholar
• Sheff ZT, Nowak CL, Maxey HL, Kelley TM. Data report: 2013 Indiana physician workforce; 2014. http://hdl.handle.net/1805/5790. Accessed August 17, 2019.
   Google Scholar
• Blouin RA, Adams ML. The role of the pharmacist in health care: expanding and evolving. N C Med J. 2017;78(3):165–167.
   PubMedGoogle Scholar
• Bush PW, Daniels R. Health care systems and transitions of care: implication on interdisciplinary pharmacy services. N C Med J. 2017;78(3):177–180.
   PubMedGoogle Scholar
• World Health Organization. Transitions of care: technical series on safer primary care; 2016. https://apps.who.int/iris/bitstream/handle/10665/252272/9789241511599-eng.pdf;jsessionid=BC203618F254FA3B486351E1EE21DEE0?sequence=1. Accessed March 25, 2020.
   Google Scholar
• Reynolds V, Causey H, McKee J, Reinstein V, Muzyk A. The role of pharmacists in the opioid epidemic: an examination of pharmacist-focused initiatives across the United States and North Carolina. N C Med J. 2017;78(3):202–205.
   PubMedGoogle Scholar
• Cochran GT, Engel RJ, Hruschak VJ, Tarter RE. Prescription opioid misuse among rural community pharmacy patients: pilot study for screening and implications for future practice and research. J Pharm Pract. 2017;30(5):498–505.
   PubMedGoogle Scholar
• Cochran G, Field C, Lawson K. Pharmacists who screen and discuss opioid misuse with patients: future directions for research and practice. J Pharm Pract. 2015;28(4):404–412.
   PubMedGoogle Scholar
• Lafferty L, Hunter TS, Marsh WA. Knowledge, attitudes and practices of pharmacists concerning prescription drug abuse. J Psychoactive Drugs. 2006;38(3):229–232.
   PubMed Web of Science ®Google Scholar
• Wenthur CJ, Cross BS, Vernon VP, et al. Opinions and experiences of Indiana pharmacists and student pharmacists: the need for addiction and substance abuse education in the United States. Res Social Adm Pharm. 2013;9(1):90–100.
   PubMed Web of Science ®Google Scholar
• American Pharmacists Association. AP. Generation RX American Pharmacists Association Academy of Student Pharmacists; 2016. https://www.pharmacist.com/apha-asp-generation-rx. Accessed March 25, 2020.
   Google Scholar
• GenerationRx. Generation Rx safe medication practices for life; 2016. http://www.generationrx.org/. Accessed March 25, 2020.
   Google Scholar
• Eukel HN, Skoy E, Werremeyer A, Burck S, Strand M. Changes in pharmacists' perceptions after a training in opioid misuse and accidental overdose prevention. J Contin Educ Health Prof. 2019;39(1):7–12.
   PubMed Web of Science ®Google Scholar
• Keller ME, Kelling SE, Cornelius DC, Oni HA, Bright DR. Enhancing practice efficiency and patient care by sharing electronic health records. Perspect Health Inf Manag. 2015;12:1b.
   PubMedGoogle Scholar
• Riley TB, Alemagno S. Pharmacist utilization of prescription opioid misuse interventions: acceptability among pharmacists and patients. Res Social Adm Pharm. 2019;15(8):1032–1036.
   PubMed Web of Science ®Google Scholar
• Dube PA, Vachon J, Sirois C, Roy E. Opioid prescribing and dispensing: experiences and perspectives from a survey of community pharmacists practising in the province of Quebec. Can Pharm J. 2018;151(6):408–418.
   Web of Science ®Google Scholar
• Webster LR. New policing role for pharmacists undermines partnership with prescribers. Pain Med. 2013;14(11):1619–1620.
   PubMed Web of Science ®Google Scholar
• Kahan M, Wilson L, Wenghofer EF, et al. Pharmacists' experiences with dispensing opioids: provincial survey. Can Fam Physician. 2011;57(11):e448-454–e454.
   Web of Science ®Google Scholar
• Marlowe KF, Geiler R. Pharmacist's role in dispensing opioids for acute and chronic pain. J Pharm Pract. 2012;25(5):497–502.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Creating community-clinical linkages between community pharmacists and physicians; 2017. https://www.cdc.gov/dhdsp/pubs/docs/ccl-pharmacy-guide.pdf. Accessed March 25, 2020.
   Google Scholar
• American Medical Association. Add a pharmacist to the team to see better outcomes; 2018. https://www.ama-assn.org/practice-management/payment-delivery-models/add-pharmacist-team-see-better-outcomes. Accessed March 25, 2020.
   Google Scholar
• Hagemeier NE, Tudiver F, Brewster S, Hagy EJ, Hagaman A, Pack RP. Prescription drug abuse communication: a qualitative analysis of prescriber and pharmacist perceptions and behaviors. Res Social Adm Pharm. 2016;12(6):937–948.
   PubMed Web of Science ®Google Scholar
• Leong C, Sareen J, Enns MW, Bolton J, Alessi-Severini S. Community pharmacy practice barriers in preventing drug misuse, divergence and overdose: a focus group study. Healthc Q. 2015;18(3):28–33.
   PubMedGoogle Scholar